SCHEMBL441985

SCHEMBL441985

O=C1[C]=CC(=O)N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7423030 0.58
SCHEMBL715867 0.53 GSK3B (1.00)
SCHEMBL28900303 0.53
SCHEMBL10990 0.53
SCHEMBL11615305 0.53
SCHEMBL693917 0.53 GSK3B (1.00)
SCHEMBL7021498 0.53
SCHEMBL33524954 0.53
SCHEMBL1768562 0.51
Charcoal, Activated SCHEMBL4128314 0.51 GSK3A (0.92)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3553 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4337639-A1 NAMPT INHIBITORS AND USES THEREOF Remedy Plan, Inc. (US) 2024-03-20 EP claimed
WO-2022241257-A1 NAMPT INHBITORS AND USES THEREOF REMEDY PLAN, INC. (US) 2022-11-17 WO claimed
US-20210052548-A1 MU OPIOID RECEPTOR MODULATORS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-02-25 US claimed
US-10702498-B2 MU opioid receptor modulators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-07-07 US claimed
US-8217050-B2 Adenine derivative as inhibitors of HSP90 for the treatment of cancer CHROMA THERAPEUTICS LIMITED (GB) 2012-07-10 US claimed
EP-2185567-B1 SUBSTITUTED BICYCLOLACTAM COMPOUNDS PFIZER PROD INC (US) 2011-03-23 EP claimed
US-20100035901-A1 ADENINE DERIVATIVE AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER CHROMA THERAPEUTICS LTD. 2010-02-11 US claimed
WO-2009136144-A1 PURINE DERIVATIVES SUITABLE FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES CHROMA THERAPEUTICS LTD (GB) 2009-11-12 WO claimed
EP-2084161-A1 ADENINE DERIVATIVES AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER Chroma Therapeutics Limited (GB) 2009-08-05 EP claimed
JP-2009518459-A 2009-05-07 JP claimed
EP-1948720-A1 METHOD FOR MODIFYING INSULATING OR SEMI-CONDUCTIVE SURFACES, AND RESULTING PRODUCTS Alchimer (FR) 2008-07-30 EP claimed
WO-2008056120-A1 ADENINE DERIVATIVES AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER CHROMA THERAPEUTICS LTD (GB) 2008-05-15 WO claimed
WO-2007048894-A1 METHOD FOR MODIFYING INSULATING OR SEMI-CONDUCTIVE SURFACES, AND RESULTING PRODUCTS ALCHIMER (FR) 2007-05-03 WO claimed
JP-2000511883-A 2000-09-12 JP claimed
WO-1997040017-A2 MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS NOVO NORDISK A/S (DK) 1997-10-30 WO claimed
EP-0069810-A1 Novel dibenzoxepins, their preparation, compositions containing them and the use of dibenzoxepins in the treatment of allergic conditions MERCK & CO. INC. (US) 1983-01-19 EP claimed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
US-12043640-B2 Prodrugs of STAT3 inhibitors TVARDI THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
EP-0000978-B1 7-AND 8-SUBSTITUTED -10,11-DIHYDRO-11-OXODIBENZO (B,F) THIEPIN DERIVATIVES, THEIR PRODUCTION AND THEIR PARMACEUTICAL COMPOSITIONS MERCK & CO. INC. (US) 1982-09-15 EP disclosed
EP-0011067-B1 PROSTAGLANDIN ANTAGONISTS, THEIR PRODUCTION AND THEIR PHARMACEUTICAL COMPOSITIONS MERCK & CO. INC. (US) 1982-04-21 EP disclosed